Improving Diagnostic Accuracy for Pediatric Immune-Mediated Necrotizing Myopathy

In pediatric neuromuscular care, we see how often one diagnosis is mistaken for another. A new case series in Frontiers in Pediatrics reminds us just how costly that confusion can be — and how the right combination of serology and genomic testing can redirect the clinical pathway for children presenting with suspected myopathies.

When the Limb-Girdle Look-Alike Steals Years

The report describes two children whose immune-mediated necrotizing myopathies (IMNMs) initially presented with the hallmarks of limb-girdle muscular dystrophy: early-onset proximal and axial muscle weakness, rhabdomyolysis, and a progressive course. One child had symptom onset at age 2 with diagnosis at 5; the other at 16 with diagnosis at 17. For families and clinicians, those intervening years shape how a child grows, moves, and engages with daily life.

What Changed the Diagnostic Path

In the first patient, myositis-specific antibody screening returned positive for anti-signal recognition particle antibodies, and muscle biopsy confirmed a pattern compatible with IMNM. That combination gave the team a clear management target: corticosteroids, intravenous immunoglobulin, and rituximab produced partial improvement in muscle strength.

The second patient followed a more difficult road. Myositis autoantibody screening was negative, and biopsy revealed a dystrophic pattern with absent dysferlin — findings that could easily have locked the team into a hereditary diagnosis. Whole-exome sequencing, however, did not identify variants that explained the muscle phenotype, leaving IMNM in the differential and protecting the child from a misdirected treatment course.

A Broader Lesson for Pediatric Immunology

For us, the principle extends well beyond two case files. Genomic and serologic testing are no longer confirmatory tools we reach for last; they are front-line instruments that shape the differential from the first clinic visit. A separate report in the Journal of Human Immunity illustrates the same point from a different angle: researchers used iterative exomic, transcriptomic, and long-read sequencing to identify a homozygous balanced translocation disrupting SAMHD1 in a 13-year-old with immune abnormalities and features consistent with familial chilblain lupus — described as the first inborn error of immunity attributed to this inheritance mechanism.

What we take back to the clinic is a simple management principle: when a child's clinical presentation overlaps with an inherited condition, push for layered testing — autoantibody panels, biopsy, and broad sequencing — before committing the family to a single diagnostic lane.

Ask explicitly whether a myositis-specific and myositis-associated autoantibody panel has been run alongside biopsy. Request whole-exome sequencing when biopsy findings could be read either as inflammatory or hereditary. And remember that a negative panel does not exclude IMNM — it simply shifts where you look next.